
News|Articles|April 1, 2003
Certain prescription cough syrups to be pulled from the market per FDAruling
An ingredient in dozens of cough syrups, which the FDA says is not dangerous,never underwent the current drug approval process because it was introducedbefore FDA efficacy guidelines were in place. The drug, extended-releaseguaifenesin, is marketed as an expectorant by 66 companies in prescriptioncough syrups.
Advertisement
Newsletter
Get the latest industry news, event updates, and more from Managed healthcare Executive.
Advertisement
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
The FDA proposes ditching comparative efficacy studies for biosimilars
2
Atopic dermatitis care advances in 2025 with new biologics, topicals and oral therapies
3
Misdiagnosis of Type 1 diabetes remains a major problem, despite advances
4
UC Davis develops new drug for bladder cancer patients
5


















































